Global Breast Biopsy Market Forecast (2017 to 2023)- Cytecare
Portland, OR — (PRESS RELEASE JET) — 09/18/2017 — Allied Market recently published a report on the global breast biopsy market for the forecast period of 2017 to 2023. The market was valued at $976.7 million in 2016 and will gain $1,420 million by 2023 registering a CAGR of 5.3%. The report opens with key benefits, an important market segment, key players and the different research methods used to structure this study.
As per recent innovation, liquid biopsy passes the test for early cancer and predicts 59% to 71% of stage I and II cancers. This technique of blood test can detect a tumor DNA from a non-tumor DNA and uses targeted error correction sequencing. Liquid biopsy development is underway that can distinguish tumor driver mutations from other alterations that might be in the blood. This novel blood test could detect the cancer cells earlier even before the patient can experience symptoms.
Latest upgrades in the 3D scanning technology are creating waves in the breast biopsy market. CareMount Medical in New York offers 3D image-guided breast biopsy with a prone system. The 360° view allows radiologists to access lesions without repositioning the patient. They installed a software enhancement that brings the best identification of abnormal regions on a breast MRI with color mapping technology.
In Bengaluru, India Cytecare hospital was announced as the first hospital to introduce Digital Breast Tomosynthesis (3D mammography) in women. 3D mammography has an upper hand over 2D scans since it uses low doses of x-rays at different angles to create multiple sequential slides through the tissues. It takes a minimum of 10 seconds for the scans and the inferences are transferred to the computer.
Lima Memorial Health Systems in the USA received a three-year recommendation for stereotactic biopsy from the American College of Radiology. This accreditation has helped preserve the center’s status as a Breast Imaging Center of Excellence being completely accredited in mammography, breast ultrasound, breast MRI, and stereotactic biopsy.
Stereotactic needle breast biopsy uses low doses of radiation to accurately point out the suspicious area. It removes multiple tissues in one insertion without causing much pain. This less invasive process leaves negligible to no scar and can facilitate doctors to diagnose smaller cancers easily.
The report contains an analysis of the breast biopsy market geography-wise. It is segmented into North America, Europe, and LAMEA. For each of the regional segments, the study mentions key market trends, market size, and forecast for each country, growth factor and opportunities.
The key players profiled are Hologic Inc, Leica Biosystems Nussloch GmbH, C.R. Bard Inc, Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Ethicon Endo-Surgery, Intact Medical Corporation, And Galini SRL.
This extensive study will enable key players and investors to understand the lucrative market areas and build strategies accordingly. The deep insights on each technological division will help them gain an understanding of the areas that contain potential.
Early buyers will get 20% customization on the report!!